Amicus Therapeutics Affirms FY2025 Sales Guidance of $607.539M-$644.520M vs $620.675M Est

Benzinga · 07/31/2025 11:14

2025 Financial Guidance

Amicus reiterates its financial guidance for 2025, as follows:

Total Revenue Growth1 15% to 22%  
Galafold Revenue Growth1 10% to 15%  
Pombiliti + Opfolda Revenue Growth1 50% to 65%  
Gross Margin Mid 80%  
Non-GAAP Operating Expenses4 $380M to $400M (Incl. $30M Upfront License Payment)
GAAP Net Income Positive during H2 2025